Long-Term Effects of AposTherapy in Patients with Osteoarthritis of the Knee: A Two-Year Followup
Table 3
Secondary outcomes.
Outcome
Baseline
Mean difference ± SE (95% CI)
value
2 years
Mean difference ± SE (95% CI)
value
Time by treatment interaction (; significance)
SF-36 PCS
Active
51.9 ± 19.2
11.8 ± 7.0
67.6 ± 16.3
30.5 ± 5.6
Control
39.7 ± 17.8
(−2.2, 25.8)
0.1
37.1 ± 14.9
(18.5, 42.6)
<0.001*
= 5.8;
SF-36 MCS
Active
64.7 ± 19.6
14.1 ± 7.2
73.7 ± 13.1
16.9 ± 4.8
Control
50.3 ± 19.7
(−0.5, 28.6)
0.1
56.8 ± 12.5
(7.2, 26.6)
<0.001*
= 0.032;
Knee Society Knee Score
Active
58.1 ± 18.8
3.4 ± 6.8
77.8 ± 12.1
17.8 ± 4.7
Control
54.1 ± 16.3
(−10.3, 17.2)
0.6
60.0 ± 14.9
(8.3, 27.3)
<0.001*
= 4.3;
Knee Society Function Score
Active
57.1 ± 16.0
8.5 ± 6.5
74.6 ± 18.3
25.2 ± 6.9
Control
47.2 ± 16.4
(−4.6, 21.7)
0.2
49.4 ± 19.3
(11.2, 39.0)
<0.001*
= 6.5;
SF-36: Short Form 36 (SF-36). was considered statistically significant. Groups showed no significant differences at the baseline. Groups showed significant differences in all outcomes after two years. There was a significant difference in improvement over time between groups in all outcomes except for the SF-36 mental component summary (MCS).
